Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
|
Sep 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
|
Feb 2018
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL)
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
|
Jul 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?
|
May 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders
|
May 2012
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality
|
Jul 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodyspla
|
Feb 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Whole exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
|
Dec 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
|
Jan 2021
|
Leukemia
|
myelodysplastic syndromes (MDS)
|